CJC / Ipamorelin

Dual-Pathway GH Signaling Blend

Growth Hormone Pulse Studies>99% (HPLC) purity

$95.00

  • FormatLyophilized powder (co-lyophilized blend), 10mg via
  • StorageStore lyophilized vial frozen; refer to COA for lot-specific stability data

This blend combines CJC-1295 and ipamorelin, two compounds associated with growth hormone signaling through different biological pathways. CJC-1295 acts as a…

50 in stock

CJC / Ipamorelin$95.00
"2 Pathways"
"Cortisol Elevation %"
Overview

About CJC / Ipamorelin

This blend combines CJC-1295 and ipamorelin, two compounds associated with growth hormone signaling through different biological pathways. CJC-1295 acts as a GHRH analogue, while ipamorelin targets the separate growth hormone secretagogue receptor (GHS-R).

Compound Information

Full Specification

Molecular FormulaBlend
Purity>99% (HPLC)
AppearanceWhite to off-white lyophilized powder
StorageStore lyophilized vial frozen; refer to COA for lot-specific stability data
FormatLyophilized powder (co-lyophilized blend), 10mg via
Molecular Structure

The CJC / Ipamorelin Molecule

An illustrative representation generated from the compound's molecular formula, alongside its logged molecular data. This figure is schematic — not a measured conformation.

Molecular Formula
Blend
CAS / IDCJC-1295 (No DAC): 863288-34-0 · Ipamorelin: 170851-70-4
Physical FormWhite to off-white lyophilized powder
Documented Purity>99% (HPLC)
Use ClassResearch Use Only
How It Works

How CJC / Ipamorelin Works

The pathways CJC / Ipamorelin acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.

CJC / Ipamorelin
GHRH-R Pathway
GHSR-1a Pathway
Synergy

Signalling pathways studied in preclinical models · illustrative

CJC-1295: GHRH Receptor Activation

GHRH-R Pathway

CJC-1295 (Modified GRF 1-29) is the GHRH receptor agonist component. It binds GHRH-R on pituitary somatotrophs, with cAMP production and GH synthesis measured. The four DPP-IV-resistant amino acid substitutions extend bioavailability to ~30 minutes, giving a longer window of GHRH-R activation per administration.

GHRH-R agonism — cAMP-mediated GH synthesis~30-minute half-life for time-matched dosingCortisol, thyroid, prolactin unaffected

Ipamorelin: Ghrelin Receptor Activation

GHSR-1a Pathway

Ipamorelin is the GHSR-1a (ghrelin receptor) agonist component. It binds a distinct receptor population on somatotrophs via a phospholipase C / IP3 intracellular pathway — separate from the cAMP route used by GHRH. This complementary signaling allows both pathways to be active simultaneously without receptor competition.

GHSR-1a agonism — PLC/IP3 intracellular pathwayNo cortisol, ACTH, or prolactin co-secretion~2-hour half-life — pulsatile GH release

Dual-Pathway Synergistic GH Amplification

Synergy

When GHRH-R and GHSR-1a are activated simultaneously, GH pulse amplitude above either compound alone has been recorded. Preclinical data describe an additive interaction between the two pathways at the pituitary.

Additive GH pulse amplitude vs either aloneSomatostatin suppression potentiated by GHSR agonismPhysiologic pulsatile pattern preserved
Uses & Applications

What CJC / Ipamorelin Is Researched For

Endocrinology

Combined GH Pathway Research

Studied for combined activity versus each compound individually.

Endocrinology

GHRH + Secretagogue Comparison

A commonly studied pairing approach in GH research.

FAQ

Common Questions About CJC / Ipamorelin

What is this blend?+

A combination of CJC-1295 (No DAC) and ipamorelin, targeting two different GH-related pathways.

Why pair a GHRH analogue with a secretagogue?+

It's a commonly studied approach for examining combined growth hormone pathway activity.

Related products